Roche Beefs Up PCR-Test Portfolio With TIB Molbiol Acquisition

Roche Holdings AG RHHBY has agreed to acquire TIB Molbiol Group for an undisclosed amount. The deal is expected to close in Q4 of 2021.
The acquisition will enhance Roche's portfolio of molecular diagnostics solutions with a wide range of assays for infectious diseases, such as identifying SARS-CoV-2 variants.
TIB Molbiol's portfolio of over 45 CE-IVD assays and more than 100 research use assays are already available on Roche's installed base of LightCycler PCR systems and MagNA Pure sample preparation systems.
The two companies have collaborated for more than 20 years to address critical healthcare needs.
Price Action: RHHBY shares closed 1.42% lower at $48.49 on Wednesday.